Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | MTHFD2 | P13995 | 4/20 | 0.52 |
| ▸ | CFTR | P13569 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3079170 | 0.86 | MAPT (0.71) | MTHFD2CFTRCYP2C9LMNAMAPT | |
| SCHEMBL31117575 | 0.79 | TRPV1 (0.68) | CFTRLMNAMAPTBAZ2BTRPV1 | |
| SCHEMBL31117415 | 0.79 | BAZ2B (0.72) | CFTRHPGDLMNAMAPTBAZ2B | |
| SCHEMBL6492381 | 0.78 | CDK4 (0.63) | MTHFD2CFTRLMNAMAPTBAZ2B | |
| SCHEMBL10818765 | 0.78 | BRD4 (0.70) | LMNA | |
| SCHEMBL9042720 | 0.77 | CFTR (0.49) | MTHFD2CFTRLMNAMAPTBAZ2B | |
| SCHEMBL10139827 | 0.77 | CFTR (0.52) | MTHFD2CFTRCYP2C9PTGDR2LMNA | |
| SCHEMBL6335099 | 0.77 | CDK4 (0.76) | TRPV1 | |
| SCHEMBL7469385 | 0.76 | HPGD (0.56) | SIGMAR1MTHFD2CYP2C9PTGDR2HPGD | |
| SCHEMBL31117450 | 0.76 | TRPV1 (0.60) | CFTRLMNAMAPTBAZ2BTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654862-B2 | Methods for the chemical synthesis of pyrrole-linked bivalent compounds, and compositions thereof | AVEKSHAN, LLC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190161491-A1 | METHODS FOR THE CHEMICAL SYNTHESIS OF PYRROLE-LINKED BIVALENT COMPOUNDS, AND COMPOSITIONS THEREOF | AVEKSHAN, LLC. | 2019-05-30 | — | — | US | disclosed |
| US-10253034-B2 | Methods for the chemical synthesis of pyrrole-linked bivalent compounds, and compositions thereof | AVEKSHAN, LLC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180072747-A1 | METHODS FOR THE CHEMICAL SYNTHESIS OF PYRROLE-LINKED BIVALENT COMPOUNDS, AND COMPOSITIONS THEREOF | AVEKSHAN, LLC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253034-B2 | Methods for the chemical synthesis of pyrrole-linked bivalent compounds, and compositions thereof | PAICS, TET3, PIN1 | SIGMAR1 4622/4885MTHFD2 32/4885CFTR 4856/4885 |
| US-10654862-B2 | Methods for the chemical synthesis of pyrrole-linked bivalent compounds, and compositions thereof | PAICS, TET3, PIN1 | SIGMAR1 4622/4885MTHFD2 32/4885CFTR 4856/4885 |
| US-20180072747-A1 | METHODS FOR THE CHEMICAL SYNTHESIS OF PYRROLE-LINKED BIVALENT COMPOUNDS, AND COMPOSITIONS THEREOF | PAICS, TET3, PIN1 | SIGMAR1 4622/4885MTHFD2 32/4885CFTR 4856/4885 |
| US-20190161491-A1 | METHODS FOR THE CHEMICAL SYNTHESIS OF PYRROLE-LINKED BIVALENT COMPOUNDS, AND COMPOSITIONS THEREOF | PAICS, TET3, PIN1 | SIGMAR1 4622/4885MTHFD2 32/4885CFTR 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.